top of page

SynaptixBio Formed to Tackle One of the World’s Rarest Diseases

Updated: Dec 16, 2021

SynaptixBio CEO and Co-Founder Dan Williams/Courtesy SynaptixBio

TUBB4a-related leukodystrophy is considered one of the rarest diseases in the world. There is no cure. But its presumed rarity hasn’t stopped a group of scientists in Oxford, UK from forming a company to treat its underlying causes.

“We’re hoping to stabilize the disease by tackling it at its source, which could lead to the extension of patients’ lives,” Dan Williams, Ph.D., CEO and co-founder of SynaptixBio, told BioSpace.

To continue reading please go to the article on BioSpace.

33 views0 comments

Recent Posts

See All

Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr

SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst

bottom of page